Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
Nanomedicine efficacy in a clinical setting depends on the pharmacological properties of the therapeutic nanoparticles. Here, the authors exemplify an accelerated translational strategy from small-scale screening to clinical scale-up for an orally-dosed aqueous paediatric HIV nanomedicine.
Guardado en:
Autores principales: | Marco Giardiello, Neill J. Liptrott, Tom O. McDonald, Darren Moss, Marco Siccardi, Phil Martin, Darren Smith, Rohan Gurjar, Steve P. Rannard, Andrew Owen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26c00fb46cdc4d1980acae4ffeece5f0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ormeloxifene nanotherapy for cervical cancer treatment
por: Chauhan N, et al.
Publicado: (2019) -
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Rahul P. Bakshi, et al.
Publicado: (2018) -
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
por: Carlos Pérez-Medina, et al.
Publicado: (2016) -
Molecular targets in arthritis and recent trends in nanotherapy
por: Roy K, et al.
Publicado: (2015) -
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
por: Yiming Zhao, et al.
Publicado: (2016)